IFP Advisors’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$721 Sell
121
-476
-80% -$2.26K ﹤0.01% 4581
2026
Q2
$2.64K Sell
597
-389
-39% -$1.66K ﹤0.01% 4106
2026
Q1
$4.31K Buy
986
+276
+39% +$1.3K ﹤0.01% 3612
2025
Q4
$3.59K Hold
710
– – ﹤0.01% 3587
2025
Q3
$2.46K Buy
710
+102
+17% +$383 ﹤0.01% 3612
2025
Q2
$2.6K Buy
+608
New +$2.03K ﹤0.01% 3774
2025
Q1
– Hold
0
– – – 4191
2024
Q4
– Hold
0
– – – 4412
2023
Q1
– Sell
-480
Closed -$8K – 3578
2022
Q4
$8K Buy
+480
New +$6.45K ﹤0.01% 3497

Other funds holding CTKB

IFP Advisors's CTKB Position: Q3 2026 in Review

IFP Advisors reduced its Cytek Biosciences (CTKB) stake by 80% in Q3 2026, selling an estimated $2.26K and leaving 121 shares worth $721. The position accounts for ﹤0.01% of the portfolio, ranked #4581.

IFP Advisors first reported a position in CTKB in Q4 2022 and has held it in 7 quarters since. The position peaked at $8K in Q4 2022. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • IFP Advisors held 121 shares of Cytek Biosciences worth $721 as of Q3 2026.
  • IFP Advisors sold 476 Cytek Biosciences shares in Q3 2026, an estimated $2.26K.
  • Cytek Biosciences made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #4581 holding.
  • IFP Advisors first reported a position in Cytek Biosciences in Q4 2022 and has held it in 7 quarters since.
  • IFP Advisors's Cytek Biosciences position peaked at $8K in Q4 2022.
  • 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.